Ashish Kumar Ghosh, Dr. Momotaz Begum. Department of Pediatric Oncology, Ankara University, Ankara, Turkey 1Department of Pediatric Endocrinology, Ankara University, Ankara, Turkey Address for correspondence: Dr.Ashish Kumar Ghosh. E-mail: ashiskumarghosh@Gmail.com Abstract Background : It has been estimated that rare tumor rate is about 15% of all childhood cancer in United States. According to Turkish Pediatric Oncology Group (TPOG) datas 3.7% of them were diagnosed as rare tumors. Aim : To investigate the frequency and clinical features of rare tumors in our pediatric oncology center. Materials and Methods: A total of 43 cases that have diagnosed as rare tumor in 574 cancer patients between the yaer 2002 and 2012 were reviewed retrospectively. All cases definitive diagnosis were established by histopathological and immunohistochemical studies. Results: Frequency of rare tumors was 7.4% in our center. Benign and border line rare tumors were 27 (62.7%) cases, malignant ra...
Posts
Rare cancers: a sea of opportunity Niki Boyd , PhD Prof Janet E Dancey Prof C Blake Gilks , MD Prof David G Huntsman , MD Volume 17, No. 2 , e52–e61, February 2016 Summary Rare cancers, as a collective, account for around a quarter of all cancer diagnoses and deaths. Historically, they have been divided into two groups: cancers defined by their unusual histogenesis (cell of origin or differentiation state)—including chordomas or adult granulosa cell tumours—and histologically defined subtypes of common cancers. Most tumour types in the first group are still clinically and biologically relevant, and have been disproportionately important as sources of insight into cancer biology. By contrast, most of those in the second group have been shown to have neither defining molecular features nor clinical utility. Omics-based analyses have splintered common cancers into a myriad of molecularly, rather than histologically, defined subsets of common cancers, ...
Treating Rare Cancer in Children: The Importance of Evidence By Alberto S. Pappo, MD Overview: The study of pediatric rare cancers, which account for approximately 9% of all childhood malignancies, has been hindered by their histologic heterogeneity and by their preferential occurrence in adolescents, a population that has been underrepresented in clinical trials sponsored by the National Cancer Institute. The use of cooperative group and investigator-initiated registries can help improve our ability to identify and select populations of patients with rare cancers that can benefit from single-arm studies, and incorporation of biologic aims and tissue banking can accelerate our understanding of the biology of these cancers. These studies should be promoted further through expansion of international outreach efforts. Well-designed preclinical models that accurately recapitulate human disease offer an attractive alternative to the study of rare cancers and may accelerat...
ডাঃ আশীষ কুমার ঘোষ শিশু রক্তরোগ বিশেষজ্ঞ সহকারী অধ্যাপক শিশু অনকোলজি বিভাগ জাতীয় ক্যান্সার গবেষণা ইন্সটিটিউট ও হাসপাতাল ঢাকা। ভূমিকাঃ হিমোফিলিয়া ( ইংরেজি: Haemophilia, অথ...